-transparent.png){kind=logo}
Dopamine metabolism was studied in various regions of rat brain by following the decline of 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-methoxy-4-hydroxyphenylacetic acid (HVA) from brain after treatment with pargyline, or from the accumulation of the acids after treatment with probenecid. The decline of DOPAC and HVA after pargyline treatment appeared exponential in all regions of brain studied with half-lives of about 13 min for HVA and 6.5 min for DOPAC. DOPAC was the major metabolite of dopamine, with various brain regions producing between 2-5 times more DOPAC than HVA. HVA accumulated after treatment with probenecid but the accumulation in 1 h did ot account for all of the HVA apparently eliminated from brain. DOPAC accumulated in some regions of brain (medulla, hypothalamus and midbrain) and not in others (cerebellum, cortex, striatum and hippocampus) after probenecid treatment. We conclude that dopamine metabolism is not uniform in brain and that the accumulation of DOPAC and HVA in brain after probenecid treatment only accounts for a minor fraction of the dopamine formed in brain.
F Karoum, and
N H Neff, and
R J Wyatt
August 1990,
Biochemical pharmacology,
F Karoum, and
N H Neff, and
R J Wyatt
May 1992,
Brain research,
F Karoum, and
N H Neff, and
R J Wyatt
January 1983,
The Journal of pharmacology and experimental therapeutics,
F Karoum, and
N H Neff, and
R J Wyatt
May 1994,
Biochemical pharmacology,
F Karoum, and
N H Neff, and
R J Wyatt
January 1983,
Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica,
F Karoum, and
N H Neff, and
R J Wyatt
January 1982,
Toxicology,
F Karoum, and
N H Neff, and
R J Wyatt
October 1995,
Sheng li xue bao : [Acta physiologica Sinica],
F Karoum, and
N H Neff, and
R J Wyatt
February 2000,
Neurochemical research,
F Karoum, and
N H Neff, and
R J Wyatt
October 1980,
Life sciences,
F Karoum, and
N H Neff, and
R J Wyatt
November 1992,
European journal of pharmacology,
